DaVita (NYSE:DVA - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 10.200-11.300 for the period, compared to the consensus earnings per share estimate of 11.440. The company issued revenue guidance of -.
Analyst Ratings Changes
Separately, Barclays boosted their price objective on shares of DaVita from $150.00 to $164.00 and gave the company an "equal weight" rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $161.80.
Check Out Our Latest Stock Analysis on DaVita
DaVita Price Performance
NYSE:DVA traded down $20.11 during mid-day trading on Monday, hitting $156.95. 5,110,690 shares of the stock traded hands, compared to its average volume of 534,172. The business's 50-day moving average price is $161.39 and its 200 day moving average price is $157.80. The company has a market cap of $12.87 billion, a PE ratio of 16.93, a price-to-earnings-growth ratio of 0.84 and a beta of 0.94. DaVita has a 12-month low of $118.56 and a 12-month high of $179.60. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78.
DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping analysts' consensus estimates of $2.14 by $0.10. DaVita had a net margin of 6.53% and a return on equity of 88.18%. On average, analysts expect that DaVita will post 9.71 EPS for the current fiscal year.
DaVita Company Profile
(
Get Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Read More
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
